Media Tip Sheet: FDA Issues Warning on First Hormone-Free Hot Flash Drug


December 18, 2024

The U.S. Food and Drug Administration has issued a black box warning for a medication used to relieve hot flashes in menopausal women.

The warning was issued for Veozah due to potential liver risks. The FDA says women taking the medication need regular blood testing to monitor liver health.

The George Washington University has experts available who can discuss this warning. If you would like to schedule an interview, please contact Katelyn Deckelbaum, [email protected].

Caitlin Murphy is a research scientist in the Department of Health Policy and Management at the GW Milken Institute School of Public Health. She is an expert in maternal and child health, women’s health, reproductive health and disparities in health among vulnerable populations.

Nancy Gaba is professor and chair of the Department of Obstetrics and Gynecology at the GW School of Medicine and Health Sciences and is board certified in Obstetrics and Gynecology.

Marie Borum is board-certified in internal medicine, gastroenterology and geriatric medicine. She is the director of the Division of Gastroenterology and Liver Diseases, and a professor at the GW School of Medicine and Health Sciences.

Lawrence Deyton is a professor of medicine at the GW School of Medicine and Health Sciences. He spent 31 years in leadership research and clinical positions in several federal health and public health agencies including the Food and Drug Administration.

-GW-